ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities July 11 2022 - 08:39AM
In a report released today, Marc Goodman from SVB Securities maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $27.00. The company's shares closed last Friday at $15.74.